Trial Outcomes & Findings for Servo-Ventilation In-lab PSG Evaluation (NCT NCT02808338)
NCT ID: NCT02808338
Last Updated: 2019-03-19
Results Overview
The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.
COMPLETED
NA
25 participants
4 nights
2019-03-19
Participant Flow
A multi-site study that accrued over 2016 and into the middle of 2017.
Participant milestones
| Measure |
Screening
All participants that consented to the study were considered for the participant flow. 15 participants were randomized to participate in the overnight in lab PSG's, these overnights were randomized to 1 of 4 interventions for each of the 4 overnights. This randomization scheme resulted in a large number of device sequences.
|
|---|---|
|
Screening
STARTED
|
25
|
|
Screening
COMPLETED
|
15
|
|
Screening
NOT COMPLETED
|
10
|
|
Overnight In-lab Polysomonography
STARTED
|
15
|
|
Overnight In-lab Polysomonography
Modified Philips BiPAP ASV
|
13
|
|
Overnight In-lab Polysomonography
ResMed S7 VPAP Adapt
|
13
|
|
Overnight In-lab Polysomonography
Philips BiPAP AutoSV Advanced System One
|
12
|
|
Overnight In-lab Polysomonography
ResMed S9 VPAP Adapt
|
12
|
|
Overnight In-lab Polysomonography
COMPLETED
|
13
|
|
Overnight In-lab Polysomonography
NOT COMPLETED
|
2
|
|
Take Home Period
STARTED
|
13
|
|
Take Home Period
COMPLETED
|
13
|
|
Take Home Period
NOT COMPLETED
|
0
|
Reasons for withdrawal
| Measure |
Screening
All participants that consented to the study were considered for the participant flow. 15 participants were randomized to participate in the overnight in lab PSG's, these overnights were randomized to 1 of 4 interventions for each of the 4 overnights. This randomization scheme resulted in a large number of device sequences.
|
|---|---|
|
Screening
Screen Failure
|
10
|
|
Overnight In-lab Polysomonography
Withdrawal by Subject
|
1
|
|
Overnight In-lab Polysomonography
Reason not given
|
1
|
Baseline Characteristics
Servo-Ventilation In-lab PSG Evaluation
Baseline characteristics by cohort
| Measure |
Screening
n=20 Participants
All participants that consented to the study.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
10 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
10 Participants
n=5 Participants
|
|
Age, Continuous
|
65.3 years
STANDARD_DEVIATION 12.6 • n=5 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
17 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
20 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
20 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
20 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 4 nightsPopulation: 1 participant was excluded because he did not meet the criteria to receive ASV.
The Apnea Hypopnea Index is the number of the apneas and hypopneas during one hour of sleep. The average of these events over one night were compared during each overnight device use.
Outcome measures
| Measure |
Philips BiPAP AutoSV Advanced System One
n=12 Participants
Philips Bilevel Postitive Airway Perssure (BiPAP) AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
|
Modified Philips BiPAP ASV
n=13 Participants
Modified Philips BiPAP AutoServoventilation (ASV): This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
|
ResMed S7 VPAP Adapt
n=13 Participants
ResMed S7 Variable Positive Airway Pressure (VPAP) Adapt: This device is FDA approved and will be set to predetermined setting.
|
ResMed S9 VPAP Adapt
n=12 Participants
ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
|
|---|---|---|---|---|
|
Average Apnea Hypopnea Index Among Different Polysomnography Devices.
|
18.4 events per hour
Standard Deviation 23.0
|
25.4 events per hour
Standard Deviation 25
|
24.1 events per hour
Standard Deviation 25.4
|
19.2 events per hour
Standard Deviation 23.1
|
Adverse Events
Philips BiPAP AutoSV Advanced System One
Modified Philips BiPAP ASV
ResMed S7 VPAP Adapt
ResMed S9 VPAP Adapt
Take Home - Modified Philips BiPAP ASV
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Philips BiPAP AutoSV Advanced System One
n=12 participants at risk
The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.
P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
Philips BiPAP AutoSV Advanced System One: Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
|
Modified Philips BiPAP ASV
n=13 participants at risk
The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
Modified Philips BiPAP ASV: This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
|
ResMed S7 VPAP Adapt
n=13 participants at risk
This is an FDA approved device and the following settings will be administered:
EEP: 4 PSmin: 3 PSMax: 16
ResMed S7 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
|
ResMed S9 VPAP Adapt
n=12 participants at risk
This is an FDA approved device and the following settings will be administered:
EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off
ResMed S9 VPAP Adapt: This device is FDA approved and will be set to predetermined setting.
|
Take Home - Modified Philips BiPAP ASV
n=13 participants at risk
After the overnight PSGs participants took home the Modified Philips BiPAP ASV for 30 days.
|
|---|---|---|---|---|---|
|
Cardiac disorders
EKG abnormalities
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
7.7%
1/13 • Number of events 1 • 40 days
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
|
Cardiac disorders
Paroxysmal Supraventricular Tachycardia
|
8.3%
1/12 • Number of events 1 • 40 days
|
0.00%
0/13 • 40 days
|
0.00%
0/13 • 40 days
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
|
Nervous system disorders
seziure
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
0.00%
0/13 • 40 days
|
0.00%
0/12 • 40 days
|
7.7%
1/13 • Number of events 1 • 40 days
|
|
Cardiac disorders
non-sustained ventricular tachycardia
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
7.7%
1/13 • Number of events 1 • 40 days
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
|
Cardiac disorders
Supraventricular Tachycardia
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
7.7%
1/13 • Number of events 1 • 40 days
|
0.00%
0/12 • 40 days
|
0.00%
0/13 • 40 days
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place